Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy

Neoplasia

Volumn 13, Issue 12, 2011, Pages 1122-1131

  Williams, Paul D ^a,i   Owens, Charles R ^b   Dziegielewski, Jaroslaw ^c   Moskaluk, Christopher A ^a   Read, Paul W ^c   Larner, James M ^c   Story, Michael D ^d   Brock, William A ^e   Amundson, Sally A ^f   Lee, Jae K ^g   Theodorescu, Dan ^b,h  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ Departments of Compendia Bioscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC RIBOSOMAL PHOSPHOPROTEIN P1; CYCLOPHILIN B; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYCLOPHILIN B GENE; GENE EXPRESSION; GENETIC MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REGULATOR GENE; SQUAMOUS CELL CARCINOMA;

EID: 84855440187     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111398     Document Type: Article

References (56)

1. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, et al. (2004). Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96, 99-106.
2. Boffetta P, Hecht S, Gray N, Gupta P, and Straif K (2008). Smokeless tobacco and cancer. Lancet Oncol 9, 667-675.
3. Riesterer O, Milas L, and Ang KK (2007). Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 25, 4075-4083.
4. Tofilon PJ and Camphausen K (2009). Molecular targets for tumor radiosensitization. Chem Rev 109, 2974-2988.
5. Sengelov L and von der Maase H (1999). Radiotherapy in bladder cancer. Radiother Oncol 52, 1-14.
6. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, and Efird JT (1993). Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329, 1377-1382.
7. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, and Kosmidis P (2001). Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 31, 43-56.
8. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, and Yonekura Y (2003). FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 30, 63-71.
9. Vidyasagar MS, Maheedhar K, Vadhiraja BM, Fernendes DJ, Kartha VB, and Krishna CM (2008). Prediction of radiotherapy response in cervix cancer by Raman spectroscopy: a pilot study. Biopolymers 89, 530-537.
10. Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D, et al. (2002). Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 20, 2980-2987.
11. Wangsa D, Ryott M, Avall-Lundqvist E, Petersson F, Elmberger G, Luo J, Ried T, Auer G, and Munck-Wikland E (2008). Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma. Br J Cancer 99, 1121-1128.
12. Sheridan MT, O'Dwyer T, Seymour CB, and Mothersill CE (1997). Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5, 180-186.
13. Minna JD, Girard L, and Xie Y (2007). Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 25, 4329-4336.
14. Williams PD, Lee JK, and Theodorescu D (2009). Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. Curr Oncol 16, 56-58.
15. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, et al. (2005). Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 65, 7169-7176.
16. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, et al. (2008). Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68, 415-424.
17. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, et al. (2009). A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75, 489-496.
18. Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, et al. (2003). Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res 9, 5486-5492.
19. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, et al. (2008). An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105, 18490-18495.
20. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, et al. (2005). Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23, 1826-1838.
21. Dumur CI, Ladd AC, Wright HV, Penberthy LT, Wilkinson DS, Powers CN, Garrett CT, and DiNardo LJ (2009). Genes involved in radiation therapy response in head and neck cancers. Laryngoscope 119, 91-101.
22. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, Looijenga LH, Scheper R, van der Wal JE, Menkema L, et al. (2009). Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124, 2643-2650.
23. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, and Theodorescu D (2007). A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 104, 13086-13091.
24. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, and Lee JK (2009). Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 69, 8302-8309.
25. Smith SC, Baras AS, Lee JK, and Theodorescu D (2010). The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 70, 1753-1758.
26. Fisher RA (1936). The use of multiple measurements in taxonomic problems. Ann Eugen 7, 179-188.
27. Venables WN and Ripley BD (2002). Modern Applied Statistics with S. Springer, New York, NY.
28. Akaike H (1974). New look at statistical-model identification. IEEE Trans Autom Control Ac19, 716-723.
29. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas-Lichius O, et al. (2007). Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120, 1731-1738.
30. Shonka DC Jr, Shoushtari AN, Thomas CY, Moskaluk C, Read PW, Reibel JF, Levine PA, and Jameson MJ (2009). Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status. Arch Otolaryngol Head Neck Surg 135, 1126-1132.
31. McKenna WG, Weiss MC, Bakanauskas VJ, Sandler H, Kelsten ML, Biaglow J, Tuttle SW, Endlich B, Ling CC, and Muschel RJ (1990). The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18, 849-859.
32. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, and Muschel RJ (1990). Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50, 97-102.
33. Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, and Dricu A (2007). Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26, 2423-2434.
34. Karin M, Yamamoto Y, and Wang QM (2004). The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3, 17-26.
35. Ahmed KM and Li JJ (2008). NF-κB-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 44, 1-13.
36. Habraken Y and Piette J (2006). NF-κB activation by double-strand breaks. Biochem Pharmacol 72, 1132-1141.
37. Magne N, Toillon RA, Bottero V, Didelot C, Houtte PV, Gerard JP, and Peyron JF (2006). NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 231, 158-168.
38. Arlt A and Schafer H (2002). NFκB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40, 336-347.
39. Fischer G, Tradler T, and Zarnt T (1998). The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. FEBS Lett 426, 17-20.
40. Kofron JL, Kuzmic P, Kishore V, Colon-Bonilla E, and Rich DH (1991). Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 30, 6127-6134.
41. Melchior A, Denys A, Deligny A, Mazurier J, and Allain F (2008). Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp Cell Res 314, 616-628.
42. Lin SY, Yang J, Everett AD, Clevenger CV, Koneru M, Mishra PJ, Kamen B, Banerjee D, and Glod J (2008). The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp Cell Res 314, 3107-3117.
43. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, Malachi T, and Gafter U (2001). Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137, 14-20.
44. Sugie N, Fujii N, and Danno K (2002). Cyclosporin-A suppresses p53-dependent repair DNA synthesis and apoptosis following ultraviolet-B irradiation. Photodermatol Photoimmunol Photomed 18, 163-168.
45. Ahlers C, Kreideweiss S, Nordheim A, and Ruhlmann A (1999). Cyclosporin A inhibits Ca2+mediated upregulation of theDNArepair enzymeDNApolymerase β in human peripheral blood mononuclear cells. Eur J Biochem 264, 952-959.
46. Herman M, Ori Y, Chagnac A, Weinstein T, Korzets A, Zevin D, Malachi T, and Gafter U (2002). DNA repair in mononuclear cells: role of serine/threonine phosphatases. J Lab Clin Med 140, 255-262.
47. Neijenhuis S, Verwijs-Janssen M, Kasten-Pisula U, Rumping G, Borgmann K, Dikomey E, Begg AC, and Vens C (2009). Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase β. DNA Repair (Amst) 8, 336-346.
48. Vens C, Dahmen-Mooren E, Verwijs-Janssen M, Blyweert W, Graversen L, Bartelink H, and Begg AC (2002). The role of DNA polymerase β in determining sensitivity to ionizing radiation in human tumor cells. Nucleic Acids Res 30, 2995-3004.
49. Vermeulen C, Verwijs-Janssen M, Begg AC, and Vens C (2008). Cell cycle phase dependent role of DNA polymerase β in DNA repair and survival after ionizing radiation. Radiother Oncol 86, 391-398.
50. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8, 816-824.
51. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98, 13790-13795.
52. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357.
53. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, et al. (2004).Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489-500.
54. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J, Dembele D, Thibault C, Muller D, et al. (2004). Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23, 2484-2498.
55. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, and Orntoft TF (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33, 90-96.
56. Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL, Mao L, Wong DT, and Zhou X (2008). Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 9, 69.